1/13/2024 0 Comments Spike protein antibody levelsPatients with cancer were more likely to have undetectable anti-S antibody responses than the general population (199 of 4249 test results vs 376 of 294 230 P < .001). There were 279 721 tests (93.72%) taken by individuals identifying as White or White British. The median age of the cohort was in the age band of 40 and 49 years and included 182 741 test results (61.22%) from women and 115 737 (38.78%) from men. ![]() The overall cohort of 228 827 individuals (patients with cancer and the noncancer population) comprised 298 479 antibody tests. Results The evaluation comprised 4249 antibody test results from 3555 patients with cancer and 294 230 test results from 225 272 individuals in the noncancer population. Main Outcomes and Measures Odds of SARS-CoV-2 breakthrough infection and COVID-19 hospitalization. Interventions Anti–SARS-CoV-2 COV-S antibody test (Elecsys Roche). This analysis ran from September 1, 2021, to March 4, 2022, a period covering the expansion of the UK’s third-dose vaccination booster program. Adults with a known or reported cancer diagnosis who had completed their primary SARS-CoV-2 vaccination schedule were included. Objective To evaluate whether spike protein antibody vaccine response (COV-S) following COVID-19 vaccination is associated with the risk of SARS-CoV-2 breakthrough infection or hospitalization among patients with cancer.ĭesign, Setting, and Participants This was a population-based cross-sectional study of patients with cancer from the UK as part of the National COVID Cancer Antibody Survey. It is not known whether SARS-CoV-2 antibody testing has clinical utility for high-risk groups, such as people with cancer. Importance Accurate identification of patient groups with the lowest level of protection following COVID-19 vaccination is important to better target resources and interventions for the most vulnerable populations. X. Lee, PhD 21 Anna Lydon, MRCP 22 Hayley McKenzie, PhD 23 Hari Panneerselvam, MBBS 24 Jennifer Pascoe, MRCP 3 Grisma Patel, MRCP 25 Vijay Patel, MBChB 16 Vanessa Potter, PhD 26 Amelia Randle, MRCP 27 Anne S. Rigg, PhD 28 Tim Robinson, PhD 29 Rebecca Roylance, MRCP 30 Tom Roques, MRCP 31 Stefan Rozmanowski, MMath 4 René L. Roux, MRCP 8 Ketan Shah, DPhil 8 Martin Sintler, MMedSci 32 Harriet Taylor 33 Tania Tillett, MBChB 34 Mark Tuthill, PhD 8 Sarah Williams, MRCP 3 Andrew Beggs, PhD 2 Tim Iveson, MD 35 Siow Ming Lee, PhD 36 Gary Middleton, MD 37 Mark Middleton, PhD 1 Andrew S. Protheroe, MD 38 Matthew W. Fittall, PhD 39 Tom Fowler, PhD 40 Peter Johnson, MD 41 for the UK COVID Cancer Programme H. Liu, MRCP 9 James R. Platt, MRes 10 Arvind Tripathy, MD 11 Isabella Watts, BMBCh 12 Sophie Therese Williams, MSc 13 Nathan Appanna 14 Youssra Al-Hajji 15 Matthew Barnard, PhD 4 Liza Benny, PhD 4 Andrew Buckley, PhD 4 Emma Cattell, PhD 16 Vinton Cheng, DPhil 9 James Clark, MBBChir 17 Leonie Eastlake, BMBS 18 Kate Gerrand, MSc 4 Qamar Ghafoor, MBChB 3 Simon Grumett, PhD 3 Catherine Harper-Wynne, MD 19 Rachel Kahn, MSc 20 Alvin J. ![]() W. Lee, DPhil 1,2 Michael Tilby, MBChB 3 Thomas Starkey, MSci 2 et al Maria C. Ionescu, MSc 4 Alex Burnett, MRCP 5 Rosie Hattersley, MBChB 6 Sam Khan, PhD 7 Martin Little, MRes 8 Justin K.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |